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Abstract
Type 2diabetes is an adult-onset condition in which the body is not able to tightly regulate the
amount of glucose in the blood and it results from a combination of causes including genetic,
behavioral and environmental factors.
Krüppel-like factor 3 (KLF3) is a zinc finger transcription factor encoded by the klf3 gene. It
has three Krüppel-like zinc fingers that bind to DNA. KLF3 inhibits adipogenesis in vitro
through its ability to inhibit an adipogenic master regulator, C/EBPα expression (Sue et al.,
2008). klf3-/- mice have fewer and smaller fat cells in adipose tissue. Reasons for different
phenotype of the klf3-/- mice than the in vitro results could be prevention of expansion of
adipocyte progenitors by premature expression of C/EBPα, likelihood of indirect processes
influencing fat pad size in vivo (Sue et al., 2008) and less food intake of klf3-/- mice. klf3-/-
mice have increased fasting blood glucose level (Unpublished data, Bell-Anderson Lab).
This variation in fasting blood glucose level suggests a role for KLF3 in glucose metabolism.
Therefore, this study was designed to investigate the mechanism underlying high fasting
blood glucose levels observed in klf3-/- mice.
Mice were sacrificed at 13 weeks of age at 5pm in a naturally fasted state and 9pm in a fed
state. Blood was collected and blood glucose and plasma glucagon levels were measured.
Liver and red quadriceps muscles were collected in order to measure glycogen and glucose-6-
phosphatase (G6Pase) activity.
Body weight of klf3-/- mice was significantly lighter than that of klf3+/+ mice (p=0.003). We
observed that klf3-/- mice had significantly higher fasting blood glucose level than klf3+/+
mice (9.8mmol/L ± 0.89 vs 8.7mmol/L ± 0.71 respectively) (p<0.05). klf3+/+ mice had
significantly higher liver glycogen level than KLF3 deficient mice in the fed state
(233.47µmol/g ± 54.48 vs 189.68µmol/g ± 38.33 respectively) (p=0.027). There was no
significant difference in muscle glycogen levels in klf3-/- and klf3+/+ mice in both fed and
fasted states. klf3-/- mice had significantly higher G6Pase activity compared to klf3+/+ mice in
the fed state (p=0.008). In the fasted state and fed state, klf3-/- mice had more or less similar
G6Pase activities which were respectively 14.1 and 14.9 µmol/g/10 minutes. There was no
significant difference in plasma glucagon levels of klf3-/- mice and klf3+/+ mice in the fasted
state. Insulin levels unchanged in KLF3 knockout and wild type mice in fed state but KLF3
knockout mice had significantly higher insulin level in fasted state (185.6µU/mL ± 57.5 vs
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112.4µU/mL ± 35.7) (p=0.004). Food intake data showed that KLF3 knockout mice eat more
food in the afternoon in which we considered as a fasted state. Therefore, the higher fasting
blood glucose levels observed in klf3-/- mice is not a result of changes in glycogen levels,
G6Pase activity, plasma glucagon and could be due to higher food intake and increased
insulin level . Results showed that KLF3 could potentially have an impact on glucose
metabolism in the fed and fasted state but further analysis on other glucose metabolic
pathways like gluconeogenesis should be performed to confirm the underlying mechanisms
for increased fasting blood glucose level of klf3-/- mice.
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11. Introduction
Type 2 diabetes is an adult-onset condition in which the body is not able to tightly regulate
the amount of glucose in the blood.  This develops as a result of insulin resistance, a lack of
response to the hormone, insulin, at the cellular level. It is known that obesity is invariably
associated with insulin resistance. Type 2 diabetes results from a combination of causes and
contributing factors including genetics, behavioral and environmental factors. Much human
research is being conducted on type 2 diabetes mellitus and associated disorders to address
clinical questions, test therapeutic interventions and prevention, but are limited in
contributing to our understanding of the molecular mechanisms underlying insulin resistance
and obesity. The use of animal models allows investigation of the involvement of specific
genes in fat formation and related processes. This can be used to identify targets for
prevention or treatment of obesity, and insulin resistance and diabetes mellitus.
Krüppel-like factor 3 (KLF3), also known as basic Krüppel-like Factor (BKLF), is a
member of the Krüppel-like factor family of transcription factors. It is a zinc finger protein
encoded by the klf3 gene. The protein contains three Krüppel-like zinc fingers that bind to
DNA (McConnell and Yang, 2010). KLF3 is a transcriptional repressor that associates with
the cofactor C-terminal binding protein (CtBP) (Pearson et al., 2008). Initially KLF3 was
thought to function as a transcriptional activator, but was later revealed to be a strong
repressor (Turner and Crossley, 1988).The tissue distribution of KLF3 in the adult mouse
includes adipose tissue, liver, lung, muscle, brain and hematopoietic tissue. Sue et al. (2008)
demonstrated that KLF3 knockout mice have fewer and smaller fat cells in adipose tissue.
Furthermore, they showed that KLF3 and CtBP play a role in the control of adipogenesis
(Sue et al., 2008). Levels of KLF3 are higher in preadipocytes and reduced upon
differentiation into adipocytes (Sue et al., 2008). Over expression of KLF3 in vitro blocks
adipocyte differentiation partly through KLF3’s ability to inhibit an adipogenic master
regulator, C/EBPα expression (Sue et al., 2008). Mouse embryonic fibroblasts that lack
KLF3 are more prone to differentiate into adipocytes, suggesting that KLF3 inhibits
adipogenesis in vivo (Sue et al., 2008).
Thus, one might expect that in the absence of this inhibitor of differentiation, we
would see increased adipocyte formation and increased white adipose tissue (WAT) mass in
KLF3 knockout mice. However KLF3 knockout mice are lean and smaller in size compared
2to their wild type litter mates. Sue et al. (2008) showed that KLF3 knockout mice have
reduced WAT mass, despite elevated levels of C/EBPα, C/EBPβ, C/EBPδ and PPARγ.
Sue et al. (2008) has proposed two possible explanations for this unexpected
observation that the KLF3 knockout mouse has less fat, whereas in culture KLF3 appears to
have an inhibitory role and KLF3 knockout fibroblasts differentiate into adipocytes more
readily than normal fibroblasts.
C/EBPα is known to be antimitotic (Turner and Crossley, 1998); thus, it is possible that in
culture in vitro its derepression and premature accumulation result in an increase in lipid-
accumulating cells, but in mice in vivo the premature expression of this antimitotic factor
prevents expansion of adipocyte progenitors and results in a smaller fat pad (Sue et al., 2008).
It is also likely that indirect processes influence fat pad size in vivo. KLF3 is broadly
expressed, and there may be subtle defects in many tissues that affect physiology and/or
behavior (Sue et al., 2008). Moreover, results of Bell-Anderson lab suggest that the
knockouts may feed less, so this could well partly explain the phenotype in vivo. Although
there are likely to be multiple factors influencing the ultimate in vivo phenotype, the results
from 3T3-L1 cells, taken together with the altered adipogenesis in KLF3 knockout fibroblasts
in culture, suggest that KLF3 does play a direct role in adipogenesis and that derepression of
C/ebpα is one contribution to the phenotype observed in the mice (Sue et al., 2008).
KLF3 deficient mice also show some variations in glucose metabolic parameters
suggesting a role for KLF3 in glucose metabolism. KLF3 could potentially be targeted for
treatments of insulin resistance and type 2 diabetes.
31.1Aims of the project
Main objective
• To investigate the mechanism underlying high fasting blood glucose levels in KLF3
deficient mice.
Specific objectives
• To assess whether there are any alterations in glucose storage capacity in KLF3
knockout mice.
• To examine whether there is any change in the activity of liver glucose 6 phosphatase,
a rate limiting enzyme in the endogenous production of glucose.
• To assess changes in levels of hormones involved in glucose homeostasis.
42. Literature Review
2.1 The Krüppel-Like Factor (KLF) family
Krüppel-Like factors (KLFs) are transcription factors (McConnell and Yang, 2010) that
contain three characteristic zinc fingers near their C terminus (Turner and Crossley, 1999 and
Suske et al., 2005). KLFs have very similar zinc finger domains to Sp1 and it’s family
members (Kaczynski et al., 2003 and Suzuki et al.,2005) and may therefore be classified as
part of the Sp1/KLF family (McConnell and Yang, 2010). Seventeen KLFs have been
identified to date (Suzuki et al., 2005 and McConnell and Yang, 2010).
2.1.1 Structure of KLFs
All members of the KLF family have three highly conserved zinc finger motifs at the
carboxy-terminal end of the protein (McConnell and Yang, 2010). Zinc finger domains are
common motifs in transcription factors. The most commonly seen zinc finger motif is the
C2H2 type (Suzuki et al., 2005), consisting of a zinc atom tetrahedrally coordinated by two
conserved cysteine and histidineresidues that allow the domain to fold into a ββα
structure(Brayer and Segal, 2008). The domains responsible for activation/repression are
found at the N-terminus of the molecule. Zinc finger location within KLF protein structures
are shown in Figure 01.
The zinc fingers in KLF proteins are linked by a “TGERP”-like motif, which assist in
binding to target DNA. (Moreover, the zinc fingers are connected by the characteristic
Krüppel link, a seven amino acid spacer TGERP) (Dang et al., 2000). The first and second
zinc fingers contain 25 amino acids, and the third contains 23 amino acids. Each zinc finger
recognizes three base pairs in the DNA sequence and interacts with nine base pairs in total
(Nagai et al., 2009).
Figure 01: KLF molecule structure.
(Source: Pearson et al., 2007).
5DNA binding sites are similar among the KLF proteins and they include GC-rich sequences
with a preference for the 5’-CACCC-3’ core motif, which is present in the β-globin gene
promoter recognized by KLF1 (Miller and Bieker, 1993). KLF proteins exhibit homology in
their carboxy-terminal zinc finger domains that allow KLFs to bind GC-rich sites in promoter
and enhancer regions of the genes they regulate. Because of these structural similarities, their
transcriptional targets can be overlapped. But KLF proteins have unique amino terminal
sequences for interaction with specific binding partners (McConnell and Yang, 2010).
Figure 02: Protein structure of human KLF family members.
(Source: McConnell  and Yang, 2010).
62.1.2 Groups of KLF family proteins
KLF proteins are grouped according to common structural and functional domains. KLFs are
highly homologous in their carboxy-terminal DNA-binding regions, which contain three
C2H2 zinc finger motifs, but can differ significantly in their N-terminal sequence.
The KLF family members are grouped based on the following:
1) the ability to bind acetylases (KLFs 1, 2, 4, 5, 6, and 7).
2) the presence of a CtBP-binding site (KLFs 3, 8, and12).
3) the presence of a Sin3A-binding site (KLFs 9, 10, 11, 13, 14, and 16). Established
sites of acetylation are marked by stars (Figure 02).
Group 1
This group includes KLFs 3, 8, and 12 (McConnell and Yang, 2010). They serve as
transcriptional repressors through their interaction with the carboxy-terminal binding protein
(CtBP).
Group 2
Family members in group include KLFs 1, 2, 4, 5, 6 and 7) function predominantly as
transcriptional activators (McConnell and Yang, 2010).
Group 3
KLFs 9, 10, 11, 13 and 14 are in this group. They have repressor activity through their
interaction with the common transcriptional corepressor Sin3A (McConnell and Yang, 2010).
2.1.3 Tissue expression of KLFs
Tissue expression of the KLFs varies. Some family members are expressed in all places in the
body (KLF6, 10 and 11) whilst other KLFs are expressed in specific tissues (McConnell and
Yang, 2010). For example, KLF1 is expressed primarily in erythroid cells whilst KLF2 is
highly expressed in lung. KLFs 4 and 5 are very plentiful in the gastrointestinal tract (Pearson
et al., 2008).  At the same time, KLFs can regulate the expression of each other. For instance,
KLF3 expression is regulated by KLF1 in erythroid cells (Funnell et al., 2007).
72.1.4 Functions of KLFs
The amino-terminal regions of KLFs vary significantly and allow them to bind different
coactivators, corepressors, and modifiers, resulting in functional diversity and specificity.
Fundamentally, KLFs regulate proliferation, differentiation, development, and programmed
cell death (McConnell and Yang, 2010). Furthermore, KLFs have roles in the physiology and
pathophysiology of many organ systems including cardiovascular, respiratory, digestive,
hematological, and immune systems (McConnell and Yang, 2010).
New biological and pathobiological roles of these KLFs are still being discovered.
Structural homologies of KLFs correlate with functional similarities.
a. Cell based functions of KLFs
I. Proliferation
Many KLFs are involved in proliferation. KLF4 and 5 are well-characterized examples
(McConnell   and Yang, 2010) and are mostly expressed in intestinal tissues. KLF4 has been
shown to inhibit cell cycle progression and is expressed at very low levels in actively
proliferating cells (Shields et al., 1996). KLF5 participates in several growth factor signaling
pathways (Dong and Chen, 2009). KLF 6 negatively (Bianchi et al., 2004) and 8 positively
(Zhao et al., 2003) regulate cell cycle progression (McConnell   and Yang, 2010). KLF 10
and 11 play important roles in cell growth control and differentiation by inhibiting cell cycle
progression (Johnsen et al., 2002 and Buck et al., 2006). Therefore KLFs regulate cell
proliferation in a variety of ways by controlling cell cycle components.
II. Differentiation
KLFs also play major roles in cell differentiation. KLFs 2, 3, 4, 5, 6, 7, 11 and 15 have been
reported to function as negative or positive regulators of adipocyte differentiation
(McConnell   and Yang, 2010). KLF1 regulates differentiation during erythropoiesis (Funnell
et al., 2007 and McConnell   and Yang, 2010) and controls the switch from expression of
fetal γ-globin to adult β-globin during the maturation of erythroid cells (Drissen et al., 2005,
8Hodge et al., 2006, Pilon et al., 2008 and McConnell   and Yang, 2010). KLF4 has also been
shown to regulate differentiation in epithelial cells of the intestinal mucosa while KLF 5
regulates differentiation of the cells at the base of the villi (Pearson et al., 2008). Katz et al.
(2002) have also shown the specific role of KLF4 in globlet cell differentiation in klf4-/-
mouse studies.
III. Apoptosis
Many studies have reported the role of KLFs in apoptosis. Mostly KLF 4, 5 and 6 function in
apoptosis. KLF4 is a tumor suppressor due to its ability to induce cell cycle arrest
(McConnell   and Yang, 2010). KLF5 is also known to be a clear suppressor of apoptosis.
Zhu et al. (2006) have observed the low levels of KLF5 in EU-8 leukemia cells and induced
expression of IAP (inhibitor-of-apoptosis protein) with introduction of ectopic KLF5. KLF6
is also a tumor suppressor (McConnell   and Yang, 2010). Moreover, KLF6 is mutated or
deleted in human prostate tumors (Narla et al., 2001) but ectopic expression of KLF6 in
prostate cancer cells or non-small cell lung cancer induces apoptosis (Ito et al., 2004 and
Huang et al., 2008).
b. Systems based functions of KLFs
I. The cardiovascular system
During embryonic development, KLF2 is expressed in vascular endothelial cells in reduced
levels (Anderson et al., 1995). Moreover, klf2-/- mice die in utero from intra-embryonic and
intra-amniotic hemorrhage (Kuo et al., 1997, Wani et al., 1998 and Lee et al., 2006). KLF5
promotes fibrosis (McConnell and Yang, 2010). Analysis of klf5+/- heterozygote mouse
revealed defects in angiogenesis and blood vessel response to injury (Shindo et al., 2002).
KLF10 is also important during development of the heart, male klf10-/- mice develop cardiac
hypertrophy by the age of 16 months (Pearson et al., 2008 and Rajamannan et al., 2007).
KLF13 is highly expressed in fetal heart (Fisch et al., 2007) and is required for cardiac
development (Martin et al., 2001 and Pearson et al., 2008). Moreover, KLF13 knockout mice
have enlarged hearts and increased susceptibility to cardiac vacuolar lesions (Gordon et al.,
92008). Fisch et al. (2007) report that expression of KLF15 in the heart increases significantly
after birth and becomes highest in the adult heart. Klf15-/- mice develop fibrosis and
deposition of excessive amounts of collagen in the heart (Wang et al., 2008) resulting in
cardiac hypertrophy (Fisch et al., 2007) demonstrating that KLF15 is a negative regulator of
cardiac fibrosis.
II. The respiratory system
Formerly known as lung KLF (LKLF), KLF2 is expressed mostly in the lung (Anderson et
al., 1995and Dang et al., 2000). KLF2 knockout mice die in utero between embryonic day
11.5 and 13.5 of embryonic life making it difficult to study the function of KLF2 in lung
development (Wani et al., 1998). However, results of some invitro studies where lung buds
embryonic stem cells were used, indicate that KLF2 is an important regulator of late-stage
lung development (Wani et al., 1999). KLF5 is expressed at high levels in the bronchiolar
epithelium and epithelial lining of the trachea (Ohnishi et al., 2000). Similarly to klf2-/- mice,
klf5-/-mice also die early in their life, therefore the exact role of KLF5 on lung development
has not been determined (Shindo et al., 2002). However Wan et al. (2008) have revealed that
KLF5 is needed for potential maturation of lung morphology and function during the saccular
stage of lung development such as regulating surfactant lipid and protein homeostasis,
vasculogenesis, maturation of the respiratory epithelium that is required for lung function
after birth. In their study, transgenic mice were generated in which the klf5 was conditionally
deleted in respiratory epithelial cells in the fetal lung and klf5-/- mice died of respiratory
distress immediately after birth (Wan et al., 2008). KLF4 may also play a role in the
pathophysiology of lung diseases such as pulmonary fibrosis and inflammatory airway
disease (McConnell and Yang, 2010).
III. Hematopoiesis
KLFs regulate erythropoiesis, lymphopoiesis, and the formation and functions of monocytes
and macrophages (McConnell and Yang, 2010). Erythropoiesis requires the highly regulated
expression of β-globin and related proteins that constitute hemoglobin. KLF1 (erythroid
KLF) plays a role in erythropoiesis by activating β-globin transcription and its expression is
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restricted to hematopoietic organs such as bone marrow and spleen (Miller et al., 1993).
KLF1 knockout mice develop fatal anemia during early fetal life when hematopoiesis starts
to occur in the liver (Nuez et al., 1995 and Perkins et al., 1995). Furthermore klf1-/- mice
produce enucleated erythrocytes which are deficient in β-globin (Nuez et al., 1995 and
Perkins et al., 1995). In addition to regulation of erythrocyte maturation, KLF1 also controls
the development of megakaryocytes (McConnell and Yang, 2010). Frontelo et al. (2007)
suggest KLF1 inhibits the formation of megakaryocytes while stimulating erythrocyte
differentiation.
Other KLFs also have been shown to regulate erythropoiesis. Expression of KLFs 2,
4, 5, and 12 increase significantly during erythroid differentiation (McConnell and Yang,
2010). KLF2 knockout mice die in utero from intra-embryonic hemorrhage (Kuo et al., 1997
and Wani et al., 1998) and studies from Basu et al. (2005) suggest that KLF2 regulates the
maturation and/or the stability of erythroid cells in the yolk sac. Klf2-/- embryos have
significantly higher number of primitive erythroid cells that undergo apoptotic cell death
(Basu et al., 2005).
KLF4 is expressed in ES cells and is one of four pluripotency genes and is capable of
reprogramming fibroblasts into ES-like cells (Wernig et al., 2007). KLF6 also appears to be
an important regulator of ES cell differentiation and hematopoiesis (Matsumoto et al., 2006).
KLF6 knockout mice die from a failure of erythropoiesis and yolk sac vascularisation
(Matsumoto et al., 2006). While KLF 2, 4 and 13 activate, KLF8 represses the γ-globin
promoter through binding to a CACCC element (Zhang et al., 2005). Interestingly KLF11 has
no effect on hematopoiesis but KLF11 is expressed in erythroid cells and can regulate the
embryonic and fetal globin expression in vitro (Emery et al., 2007).
IV. The immune system and inflammatory responses
KLFs have also been implicated in T cell function. KLF2 is down-regulated upon activation
of T-cells in vivo (Dang et al., 2000). Kuo et al. (1997) found that KLF2 is highly expressed
in the thymus and medulla like lymphoid organs and that KLF2 inhibits activation, growth,
and proliferation of T-cells (Kuo et al., 1997). KLF10 is also important in regulating T cells
(Fontenot et al., 2005). Not only KLF2 and 10, but KLF13 also plays a role in T cell
activation, survival and development (McConnell and Yang, 2010). Klf13-/- mice have
enlarged thymuses and spleens as a result of decreased T-cell apoptosis (Pearson et al., 2007
11
and Zhou et al., 2007). Outram et al. (2008) also suggest that KLF13 influences multiple
stages of B- and T-cell development in vivo.
As far as B-cells are concerned, KLF4 plays an important role in B-cell function as a
positive regulator of B-cell proliferation (McConnell and Yang, 2010).Van Zelm et al. (2005)
show that KLF4 is expressed in early stage B-cell precursors, at the time of immunoglobin
gene rearrangement and expression continuously increases until B-cells become matured
(Klaewsongkram et al., 2007).
It has also been found that KLFs regulate signaling of macrophages in response to
inflammatory cytokines such as IFN-γ, LPS, or TNF-α thereby mediating the development of
acute and chronic inflammatory disorders (McConnell and Yang, 2010). KLFs also play an
important role in monocyte differentiation. For instance, KLF4 regulates monocyte
differentiation in vitro and in vivo (Feinberg et al., 2007 and Alder et al., 2008). In contrast,
KLF2 inhibit monocyte activation (Das et al., 2006). Liao et al. (2011) report that KLF4
function as an important regulator of macrophage polarization. Macrophage KLF4 expression
was highly induced in M2 macrophages and strongly reduced in M1 macrophages (Liao et
al., 2011). M1 macrophagesare proinflammatory while M2 macrophages are anti-
inflammatory. Liao et al. (2011) report that KLF4 knockout mice exhibited delayed wound
healing.
V. The digestive system
It has been revealed that KLFs 4 and 5 play an important role in maintenance of intestinal
epithelial homeostasis (McConnell et al., 2007 and Ghaleb et al., 2005) and are expressed
highly in adult intestinal epithelial cells (Ton-That et al., 1997, Ohnishi et al., 2000 and Dang
et al., 2007). KLF4 inhibits cell proliferation and KLF5 promotes it (Chanchevalap et al.,
2004, Ghaleb et al., 2005, McConnell et al., 2007 and Shields et al., 2006). Zhang et al.
(2007) demonstrate that KLF5 also mediates the induction of proliferation of colon cancer
cells by lysophosphatidic acid (LPA).
It has been revealed that KLF6 regulates the early stages of fibrotic response during
liver injury (McConnell and Yang, 2010). Hepatic stellate cells (HSCs) are the major source
of extracellular matrix during liver fibrosis and they are activated upon liver injury and
during subsequent wound healing (Friedman, 2008). Using rat models it has been shown that
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KLF6 is induced during early phase of HSC activation (Lalazar et al., 1997 and Ratziu et al.,
1998).
KLF9 regulates intestinal morphogenesis (McConnell and Yang, 2010) while
expressed in smooth muscle cells (SMCs) of the small intestine and colon (Simmen et al.,
2007). Furthermore Simmen et al. (2007) showed that the jejunum of klf9-/- mice has shorter
villi and reduced proliferation of crypt cells.
KLF11 is highly expressed in the pancreatic beta cells. KLF11 regulates the β-cell
function by playing a role in glucose signaling in pancreatic beta cells (Neve et al., 2005).
Neve et al. (2005) report that KLF11 is inducible by glucose and up-regulates levels of
insulin expression in pancreatic beta cells. In addition, KLF11 represses key genes encoding
scavengers of oxidative stress such as SOD2 (Superoxide dismutase 2) and catalase resulting
in oxidative stress. This observation is extremely important because a tight control of
oxidative stress is critical for maintaining the homeostasis of pancreatic beta cells (Neve et
al., 2005).
VI. Bone metabolism
KLF10 is the only known KLF family member to date shown to regulate bone metabolism
(McConnell and Yang, 2010). Subramaniam et al. (2005) demonstrated that KLF10 knockout
mice have a greater number of osteoblasts, but not osteoclasts during bone formation than
wild type mice. However, osteoblasts from klf10-/- mice fail to mineralize and support the
differentiation of osteoclasts (Subramaniam et al., 2005).  As a result, KLF10 knockout mice
have defects in bone and tendon strength and microarchitecture (Subramaniam et al., 2005
and Bensamoun et al., 2006). Moreover, Yerges et al. (2010) showed that KLF10 was one of
five genes whose expression was associated with volumetric bone density in a SNP study of
genes related to bone metabolism.
VII. The nervous system and neuronal morphogenesis
KLFs also have a role in neuronal morphogenesis (McConnell and Yang, 2010). KLF4 was
recently identified as an important factor regulating the functions of neurons in the CNS
(Moore et al., 2009).  It has been shown that retinal ganglion cells (RGCs) lacking KLF4
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have increased axon growth both in vitro and after optic nerve injury in vivo. Thus KLFs act
as positive and negative regulators within the nervous system.
KLF7 is also highly expressed in neuronal tissues and KLF7 knockout mice are
neonatally lethal (Laub et al., 2005).
KLF9 is necessary for some neuron development and neurogenesis. It has been found
that KLF9 is expressed in a region called the dentate granule (DG) of the mammalian brain in
which neurogenesis occurs in adulthood (Scobie et al., 2009). Furthermore, DG neurons from
klf9-/-mice showed delayed maturation, and adult KLF9 knockout mice have impaired
differentiation of adult-born neurons (Scobie et al., 2009).
VIII. Tumor biology
Many KLFs are involved in the pathology of cancer in vivo (McConnell and Yang, 2010).
KLF4 is known to be a tumor suppressor of cancers in colon (Zhao et al., 2003), esophagus
(Wang et al., 2002), stomach (Cho et al., 2007), pancreas (Wei et al., 2008), lung (Hu et al.,
2009), prostate (Foster et al., 2000) and the urinary bladder (Ohnishi et al., 2003). At the
same time, there are controversial data suggesting that KLF4 can promote tumor formation.
For instance high levels of KLF4 mRNA and protein are present in breast tumor samples
(Foster et al., 2000). KLF4 is present in squamous cells of skin and oral cavity and it involves
in pathogenesis of carcinoma in squamous cells (Foster et al., 2000). KLF6 is also
deregulated in prostate (Narla et al., 2001) and liver cancer (Bureauet al., 2008).
IX. Metabolic regulation
The most reported roles for KLFs involved in metabolism are in the regulation of the
differentiation of fat cells or adipocytes (McConnell and Yang, 2010). Brey et al. (2009)
propose that KLFs are an important part of the regulatory cascade that leads to adipogenesis.
KLF family members contribute to the transcriptional control of adipogenesis both positively
and negatively (figure 03). Table 01 summarizes the effect of KLFs on adipogenesis.
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Figurer 03: Contribution of KLFs in regulating adipocytes differentiation.
(Source: Nagai et al., 2009).
Table 01: Functions of KLFs in relation to adipogenesis.
Type of KLF Function Reference
KLF2 (LKLF) Inhibit adipocytes differentiation, expression is higher in
undifferentiated preadipocytes and reduced upon
differentiation into adipocytes.
Overexpression blocks adipocyte differentiation partly
through KLF2’s ability to repress PPARγ expression
(PPARγ is a master regulator of adipocyte
differentiation).
Mouse embroyonic fibroblasts that lack klf2 are more
prone to differentiate into adipocytes, indicating that
KLF2 inhibits adipogenesis in vitro.
Banerjee et al.,
2003, Wu et al.,
2005
Banerjee et al., 2003
Wu et al., 2005
KLF3 Inhibits adipocyte differentiation in vitro, expression is
higher in preadipocytes and reduced upon differentiation
into adipocytes.
Over expression blocks adipocyte differentiation partly
through KLF3’s ability to inhibit C/EBPα expression.
Mouse embroyonic fibroblasts that lack klf3 are more
prone to differentiate into adipocytes, indicating that
KLF3 inhibit adipogenesis in vitro.
Over expression of KLF3 blocks differentiation of 3T3-
L1 cells in a CtBP dependent manner. CtBP binds
NADH, and is a putative metabolic sensor for KLF3-
Sue et al., 2008
Sue et al., 2008
McConnell and
Yang, 2010
15
related repressor function.
KLF4 Promotes adipogenesis.
Knockdown of KLF4 inhibits adipogenesis and reduces
the C/EBP β levels in 3T3-L1 cell cells.
Birsoy et al., 2008
KLF5 Promotes adipogenesis.
Induces adipocyte differentiation.
Oishi et al., 2005
KLF6 Promotes adipogenesis.
Delta-like 1 (Dlk-1) or preadipocyte factor-1 (Pref-1)
regulates adipogenesis by preventing differentiation of
3T3-L1 cells in to adipocytes.
KLF6 represses Dlk-1 expression and thereby stimulates
3T3-L1differentiation.
Knockdown of KLF6 prevents adipogenesis.
Smas and Sul, 1993
Li et al., 2005
KLF7 Expression of KLF7 is decreased upon 3T3-L1 adipocyte
differentiation and over expression of KLF7 inhibits
adipogenesis.
Expression of KLF7 in human preadipocytes inhibited
their differentiation and was associated with a reduction
in expression of C/EBPα and PPARγ.
Over expression in differentiated adipocytes reduced the
level of adipokines viz. leptin and adiponectin.
Kanazawa et al.,
2005
KLF11 KLF11 shown to regulate cholesterol-mediated gene
expression. In that KLF11 represses the caveolin-1 gene
that is involved in cholesterol homeostasis.
Cao et al., 2005
KLF15 KLF15 regulates adipocyte differentiation through its
regulation of PPARγ expression.
Its expression is highly promoted during differentiation
of 3T3-L1 preadipocytes into adipocytes.
RNA interference of KLF15 reduces expression of
PPARγ and block the adipogenesis of 3T3-L1
preadipocytes.
KLF15 and C/EBPα act synergistically to increase the
activity of PPARγ2 in 3T3-L1 adipocytes.
Mori et al., 2005
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2.2 Krüppel-Like factor 3 (KLF3)
Krüppel-like factor 3 is a protein in humans that is encoded by the KLF3 gene (Sue et al.,
2008). KLF3 was first identified in an erythroid screen for factors related to KLF1 (Crossley
et al., 1996). Initially KLF3 was thought to function as a transcriptional activator, but later it
was revealed that KLF3 is a strong repressor of transcription (Turner and Crossley, 1998).
In a yeast two-hybrid screen, KLF3 was found to interact with the transcriptional co-
repressor C-terminal binding protein (CtBP) (McConnell and Yang, 2010). KLF3 is a more
potent transcriptional repressor when bound to CtBP. KLF3's PVDLT (amino acids 61-65)
domain, present in its N-terminal variable region, is necessary for its interaction with CtBP
(Sue et al., 2008). KLF3 binds CtBP in its NADH-activated state, suggesting that KLF3
regulates transcription in response to the redox state of the cell (Sue et al, 2008).
2.2.1 Tissue distribution of KLF3
KLF3 is broadly expressed in tissues of the mouse, including liver (Funnell et al., 2007),
lung, skeletal muscle (Himeda et al., 2010), brain and adipose tissue (Sue et al., 2008) but is
particularly abundant in hematopoietic tissues (Funnell et al., 2007).
KLF3 deficient mice are smaller in size compared to wild type mice (Figure 04) and
KLF3 knockout mice have smaller and fewer fat cells (adipocytes). Additionally, most organs
are proportionally smaller in klf3-/- mice compared to wild type mice (Sue et al., 2008).
Figure 04: Wild type mouse (left) and KLF3 knock out mouse (right).
(Source: Bell-Anderson lab, School of Molecular Bioscience, The University of Sydney).
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2.2.2 Functions of KLF3
The physiological roles of KLF3 are mostly unknown. KLF3 has been shown to bind in vitro
to CACCC elements in the promoter regions of many erythroid genes, such as adult β-globin,
fetal γ-globin, Gata-1, carbonic anhydrase I, porphobilinogen deaminase (Pbgd), and
pyruvate kinase (Funnell et al., 2007). Since CACCC-binding activity of KLF3 is more
readily detected in yolk sac and fetal liver, is has been suggested that KLF3 has a role in
hematopoiesis (Funnell et al., 2007).
As previously mentioned, KLF3 can also regulate the adipogenic process. klf3 mRNA
and protein levels are high initially but decline as adipogenesis progresses (Sue et al., 2008).
Microarray analyses have previously suggested that CtBP may be involved in repressing
c/ebpα (Grooteclaes et al., 2003).
The PPAR and C/ebp family of transcription factors are master regulators of
adipogenesis especially during terminal differentiation and maturation of adipocytes (Sue et
al., 2008). As KLF3 expression diminishes, C/ebpα expression also increases. Forced over-
expression of KLF3 in the 3T3-L1 system blocks adipogenesis, but a mutant form of KLF3
that cannot bind the co-repressor CtBP is ineffective. This result implicates a CtBP-
dependent role for KLF3 in the control of adipogenesis (Sue et al., 2008). Sue et al. (2008)
also demonstrated that KLF3 and CtBP repress the C/ebpα promoter. This is consistent with
the fact that functional CACCC boxes have been identified in the C/ebpα promoter and that
C/ebpα has previously been listed as a gene that is depressed in CtBP knockout cells
(Grooteclaes et al., 2003).
KLF3 is also a transcriptional regulator of skeletal muscle genes (Himeda et al.,
2010). This research group showed that KLF3 transcripts and protein increase during muscle
differentiation and KLF3 is enriched at the promoters of endogenous muscle genes. In that
KLF3 and SRF (serum response factor) synergize in trans-activating the MCK (muscle
creatine kinase) promoter. But KLF3 knockout mice have no apparent muscle defects
(Himeda et al., 2010).
Vu et al. (2011) have revealed a function of KLF3 in B cell development by studying
B lymphopoiesis in a klf3-/- mouse model. B cell differentiation is significantly impaired in
the bone marrow, spleen, and peritoneal cavity of KLF3 null mice (Vu et al., 2011).
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2.2.3 Role of KLF3 in energy metabolism
As previously described, KLF3 has a role in adipogenesis. Furthermore, a role for KLF3 in
glucose metabolism has also begun to unravel. According to the unpublished data of Bell-
Anderson lab, KLF3 knockout mice have increased fasting blood glucose levels compared to
their wild type littermates. However at this stage, mechanisms underlying these observations
are not clear.
Figure 05: Blood glucose levels in male mice fasted for 15h, preceding glucose tolerance
test. The effect of genotype by ANOVA across all groups is p<0.01.
(Source: Bell-Anderson lab, School of Molecular Bioscience, The University of Sydney).
2.3 Carbohydrate metabolism
Figure 06: Summary of carbohydrate metabolism in the liver.
(Source: Ophardt, 2003)
Glycogenesis
Glycogenolysis
Pyruvic acid
Glycolysis Gluconeogenesis
Carbohydrates (glucose,
fructose, galactose)
Glycogen GlucoseG-6-PO4
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2.3.1 Glucose as an energy source of the body
Glucose is a monosaccharide which represents an essential biological energy source, enabling
the generation of ATP following glycolysis. Although many tissues can also use fats and
protein as an energy source, the brain and red blood cells can only use glucose. Glucose is
stored in the body, importantly in the liver, as glycogen.
2.3.2 Glycolysis
Glycolysis is a two stage catabolic pathway in which each glucose molecule is converted to
two molecules of pyruvate.
Stage 01: Glucose is phosphorylated and cleaved to form two molecules of Glyceradehyde-3-
phosphate (G-3-P). Two ATP molecules are consumed during this step.
Stage 02: G-3-P is converted to pyruvate. Four ATP and two NADH molecules are produced
in this step. Since two molecules of ATP are consumed in stage 01, net production of ATP
per glucose molecule is two.
2.3.2.1 The reactions of the glycolytic pathway
The reactions of the glycolysis pathway are shown in Figure 07 in green color arrows.
Glycolysis is stimulated as the energy charge falls down (Berg et al., 2002).
In metabolic pathways, enzymes catalyzing essentially irreversible reactions are
potential sites of control. In glycolysis, the reactions catalyzed by hexokinase,
phosphofructokinase, and pyruvate kinase are virtually irreversible. Therefore these enzymes
would be expected to have regulatory as well as catalytic roles. The inhibition and activation
of these enzymes and how those will affect on glycolysis will be discussed in 2.3.6 section in
detail.
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2.3.2.2 Fate of pyruvate
Pyruvate, the product of glycolysis, is an energy rich molecule. Pyruvate can be metabolized
in the following pathways in order to produce energy.
(a) Under aerobic conditions, most cells in the body convert pyruvate into acetyl-CoA
which is then entersthe citric acid (TCA) cycle resulting in complete oxidization to CO2 and
H2O.
(b) In muscle cells, red blood cells and certain bacterial species, pyruvate is converted to
lactate in the lactate dehydrogenase reaction (Tornheim and Ruderman, 2011).
Pyruvate + NADH + H+ Lactate + NAD+
In rapidly contracting muscle cells, the demand for energy is high. After depletion of oxygen,
lactic acid fermentation provides sufficient regeneration of NAD+ to allow glycolysis to
continue.
2.3.3 Gluconeogenesis
Maintenance of blood glucose levels during fasting and prolonged exercise are essential for
proper functioning of the brain and nervous system. During brief fasting, the blood glucose
concentration is topped up through the breakdown of liver glycogen.  When fasting is
prolonged and glycogen levels are depleted, glucose is formed from non-carbohydrate
sources such as lactate, pyruvate, glycerol and other amino acids in a process known as
gluconeogenesis. This mainly takes place in the liver. Renal gluconeogenesis contributes to
systemic glucose pool only during periods of extreme starvation (Aronoff et al., 2004).
Although most tissues have the ability to hydrolyze glycogen, only the kidney and liver
contain glucose-6-phosphatase, the enzyme- responsible for releasing glucose back into the
circulation.
Gluconeogenesis uses many of the same reactions as glycolysis in reverse (Tornheim
and Ruderman, 2011) and the reactions of gluconeogenesis are shown in Figure 07 in blue
color arrows.
21
Glucose
Glucose-6-phosphate
Fructose-6-phsphate
Frucitose-1,6-bisphosphate
Glyceraldehyde-3-phosphate (2)
1,3-bisphosphoglycerate (2)
3-phosphoglycerate (2)
2-phosphoglycerate (2)
Phosphoenolpyruvate (2)
Pyruvate (2)
Figure 07: The reactions of glycolysis and gluconeogenesis.
(Source: Berg et al., 2002)
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2.3.3.1 Regulation of gluconeogenesis
Gluconeogenesis is an energy consuming process. The energy for this obviously cannot come
from glycolysis. The synthesis of a glucose molecule requires the release of six high energy
phosphate bonds; two each at the reactions catalyzed by pyruvate carboxylase, PEPCK and
phosphoglycerate kinase.
As with other metabolic pathways, the rate of gluconeogenesis is affected by substrate
availability, allosteric effectors and hormones. Gluconeogenesis is stimulated by high
concentrations of lactate, glycerol and amino acids. A high-fat diet, starvation and prolonged
fasting make large quantities of these molecules available (Feliget al., 1969).
Control of net gluconeogenesis involves regulation of key glycolytic enzymes and the
opposing gluconeogenic enzymes (Tornheim and Ruderman, 2011). The four enzymes
specific to gluconeogenesis (pyruvate carboxylase, PEPCK, fructose-1,6-bisphosphatase and
glucose-6-phosphatase) are regulated by allosteric modulators such as acetyl CoA, level of
ATP and AMP (Thabrew and Ayling, 2001).
Hormones also regulate gluconeogenesis by altering synthesis of key rate limiting
enzymes (Tornheim and Ruderman, 2011). Importantly, whether either glycolysis or
gluconeogenesis is active is largely determined by ratio of insulin to glucagon. After a
carbohydrate meal, the insulin/glucagon ratio is high and glycolysis in the liver predominates
over gluconeogenesis (Tornheim and Ruderman, 2011). After a period of fasting or following
a high fat, low carbohydrate meal, the insulin/glucagon ratio is low and gluconeogenesis in
liver predominates over glycolysis. Glucagon, a signal of low glucose levels, causes
phosphorylation of Frucotse-2,6-bisphosphate Into Fructose-6-phosphate and promotes net
gluconeogenesis. Glucagon depresses the synthesis of fructose-2,6-bisphosphate, which
releases the inhibition of fructose-1,6-bisphosphatase and inactivates pyruvate kinase
(Tornheim and Ruderman, 2011). Furthermore glucagon favors gluconeogenesis and leads to
additional synthesis of PEPCK, fructose-1,6-bisphhosphatase  and glucose-6-phosphatase.
Insulin depresses the synthesis of PEPCK, fructose-1,6-bisphhosphatase  and glucose-6-
phosphatase.
Ppyruvate kinase is allosterically inhibited by ATP and alanine. The availability of
ATP is also an important regulator in the control of gluconeogenesis or glycolysis. At high
levels of AMP, a low-energy hydrolysis product of ATP, flux through glycolysis is increased
at the expense of gluconeogenesis, conversely, low levels of AMP increase the flux through
gluconeogenesis at the expense of glycolysis (McKee and McKee, 2011).
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2.3.4 Glycogen as a source of stored energy in the body
Glycogen stores provide readily available glucose to supply the tissues with an oxidizable
energy source. Glycogen is a polymer of glucose residues linked by α-(1,4)- and α-(1,6)-
glycosidic bonds (Figure 08). Glycogen stores are found principally in the liver. A second
major source of stored glucose is the glycogen of skeletal muscle. While liver has a greater
concentration of glycogen per -gram of weight, total glycogen is higher in muscle because of
its larger tissue mass. The purpose of liver glycogen reserve is to break down when glucose is
needed and to supply to other tissues, particularly the brain. Muscle glycogen supplies local
glycolytic fuel for muscle contraction. However, muscle glycogen is not generally available
to other tissues, because muscle lacks the enzyme glucose-6-phosphatase.
Figure 8: Structure of glycogen.
2.3.5 Glycogen metabolism
The synthesis and degradation of glycogen are regulated in order to provide sufficient
glucose for the body’s needs. Both glycogenesis and glycogenolysis are primarily controlled
by three hormones: insulin, glucagon and epinephrine (McKee and McKee, 2011).
2.3.5.1 Glycogenesis
Glycogen is synthesized when blood glucose levels are high after a meal, and especially after
a carbohydrate rich meal. The synthesis of glycogen involves the following reactions
illustrated in Figure 09 (arrows at top in maroon color).Glucagon hormone can inhibit the
glycogen synthase stopping the formation of glycogen.
α-1,4-glycosidic linkages
α-1,6-glycosidic linkages
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Glucose G-6-P G-1-P Glycogen
Figure 09: Major reactions of glycogenesis and glycogenolysis (GPK: glycogen
phosphorylase kinase).
2.3.5.2 Glycogenolysis
This is the breakdown of glycogen to glucose. During the first 8-12 hours of fasting,
glycogenolysis in the liver plays a major role in maintaining blood glucose levels by releasing
glucose into the blood stream. Reactions of glycogenolysis are shown in Figure 09 (arrows at
bottom in orange color).
In glycogenolysis, glycogen stored in liver and muscles, is first converted into
glucose-1-phosphate (G-1-PO4) by breaking α(1,4) linkages (Tornheim and Ruderman,
2011). Glucose-1-phosphate, the major product of glycogenolysis is diverted to glycolysis in
muscle cells to generate energy for muscle contraction (McKee and McKee, 2011). In
hepatocytes, glucose-1-phosphate is converted to glucose by phosphoglucomutase and
glucose-6-phosphatase (McKee and McKee, 2011).
The rate of glycogenolysis is under the influence of the hormones glucagon and
insulin from the pancreas and epinephrine from the adrenal glands. Whilst glucagon and
epinephrine trigger glycogenolysis, insulin suppresses it.
Glucagon
-
Glycogenesis
Glucose kinase &
hexose kinase
Glycogen
synthase
Glycogen
phosphorylase
G-6-Pase
Glycogenolysis
GPK
+
Glucagon +
+
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2.3.6 Key enzymes involved in glucose metabolism
(1) Glucose-6-phosphatase (G6Pase)
G6Pase is an enzyme present in liver that plays an important role in glucose homeostasis in
the body. It hydrolyzes glucose-6-phosphate resulting in a phosphate group and free glucose
during starvation (Schaftingen and Gerin, 2002), therefore it is an enzyme involved in hepatic
glucose production. Moreover, both gluconeogenesis and glycogenolysis result in glucose-6-
phosphate, which is hydrolyzed by G6Pase (Nordlie and Sukalski, 1985). G6Pase is a
membrane-bound enzyme associated with the endoplasmic reticulum (Schaftingen and Gerin,
2002). In humans, there are three isozymes, G6PC, G6PC2, and G6PC3. G6Pase deficiency
is responsible for glycogen storage disease type I (GSD I) (Cori and Cori, 1952 and Arion et
al., 1975).
(a) Role of Glucose 6-phosphatase in energy metabolism
Recent studies have indicated that G6Pase has a key role in the regulation of hepatic glucose
production. G6Pase does not act on glucose-1-phosphate (G-1-P) or fructose-6-phosphate (F-
6-P) (Cori and Cori, 1952). Both must first be converted to glucose-6-phoshate (G-6-P) the
only hexose monophosphate that is split by G6Pase.
Glycogen G-1-P G-6-P Glucose
The production of glucose from non carbohydrate sources includes the following reactions as
final steps (Swanson, 1949).
Triosephosphates HDP F-6-P G-6-P Glucose
.
(2) Phosphofructokinase
Phosphofructokinase (PFK) catalyses the addition of phosphate to fructose-6-phosphate to
form fructose-1,6-bisphosphate. This reaction is an important control point in glycolysis. PFK
is inhibited by high level of ATP, a fall of pH, and activated by ADP, AMP, Pi, fructose-1,6-
bisphosphate, fructose-2,6-bisphosphate and excessive formation of lactic acid (Thabrew and
G6PaseMutasePhosphorylases
G6Pas
e
IsomerasesPhosphatasesAldolase
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Ayling, 2001). Recently it has been found that phosphofructokinase-M (muscle type)
deficient mice have greatly reduced fat stores, despite the presence of the other two isoforms
(liver and platelet types) in fat. This suggests the possible importance of glycolytic
oscillations for glycerol-3-phosphate generation as precursors for triglyceride synthesis
(Getty-Kaushik et al., 2010).
(3) Hexokinase
Hexokinase is usually considered as the first enzyme in glycolysis. Hexokinase can follow
the lead of PFK because hexokinase is inhibited by glucose 6-phosphate (Tornheim and
Ruderman, 2011). Hexokinase, but not glucokinase, is inhibited by glucose-6-phosphate.
Thus, this allows hexokinase to be responsive to the demand for glucose-6-phosphate in the
cell. Thus, if PFK is inhibited, the concentration of glucose-6-phosphate will rise and inhibit
hexokinase, on the other hand, when PFK is activated, such as by muscular contraction, and
fructose-6-phosphate levels drop, the concentration of glucose-6-phosphate will also fall and
hexokinase will be de-inhibited. Use of glucose-6-phosphate for glycogen synthesis would
also alleviate the inhibition of hexokinase (Tornheim and Ruderman, 2011).
(4) Pyruvate dehydrogenase (PDH)
Pyruvate dehydrogenase is an enzyme responsible for the oxidation of pyruvate to acetyl
CoA using NAD and CoA producing NADH and CO2. Regulation of this step is very
important because, although acetyl CoA can be incorporated into fatty acids or made from
fatty acids, carbons at this stage cannot be converted back to glucose. The regulation of PDH
is on two levels.
1. Acetyl-CoA and NADH inhibit PDH at active sites, in competition with the
respective substrates, CoA and NAD. So Acetyl CoA/CoA and NADH/NAD ratios
are the important inhibitory parameters.
2. The PDH complex is inactivated by phosphorylation by PDH kinase
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PDH is inhibited if there is already plenty of acetyl CoA to enter the citric acid cycle, or
NADH for the electron transport chain and oxidative phosphorylation, or ATP. On the other
hand, if there is a lot of pyruvate or high blood glucose levels, there is no need to spare the
pyruvate as indicated by high plasma insulin levels.Sugden et al. (1995) demonstrated that
insulin activates PDH.
2.3.7 Glucose homeostasis
Plasma glucose concentration is a function of the rate of glucose entering the circulation
balanced by the rate of glucose removal from the circulation. Blood glucose is derived from
three sources:
 intestinal absorption during the fed state (dependent on rate of gastric
emptying).
 glycogenolysis.
 gluconeogenesis.
2.3.7.1 Imbalance of glucose - diabetes mellitus
The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism
resulting from defects in insulin secretion, insulin action, or both. The effects of diabetes
mellitus include long-term damage, dysfunction and failure of various organs (WHO, 1999).
There are three main types of diabetes mellitus (DM).
Type 1 DM results from the body's failure to produce insulin, and currently requires
the person to inject insulin or wear an insulin pump (WHO, 1999).
Type 2 DM results from insulin resistance, a condition in which cells fail to use
insulin properly, sometimes combined with an absolute insulin deficiency (WHO, 1999).
The third main form, gestational diabetes, occurs when pregnant women without a
previous diagnosis of diabetes develop a high blood glucose level. It may precede
development of type 2 DM (WHO, 1999).
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Figure 10: Glucose homeostasis at fed state in a non-diabetic (left)
and diabetic subject (right).
(Source: Aronoff et al., 2004).
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(a) High blood glucose level (fed state)
After a meal, glucose is released in to the blood stream resulting in higher blood glucose
levels. At the immediate post meal stage, insulin is secreted into the circulation by β-cells in
the islets of Langerhans which make up the endocrine pancreas. Insulin binds to insulin
receptors in plasma membrane of target tissues. Activation of insulin signal transduction
facilitates the movement of glucose transporter vesicles to the plasma membrane to increase
glucose uptake into the cell and reduce blood glucose levels. Intracellularly, insulin
stimulates the conversion of glucose in to glycogen and fat (Figure 10, left diagram). In the
fed state, endogenous glucose production in the liver is also suppressed by,
 the direct action of insulin, delivered via the portal vein, on the liver.
 the direct communication within the pancreas between β- and α-cells,
resulting in suppression of glucagon synthesis and secretion.
Figure 11: Balance between glucose appearance in the circulation and glucose disappearance
or uptake. Glucose appearance is a function of hepatic(endogenous) glucose production and
meal-derived sources and is regulated bypancreatic and gut hormones. (Source: Aronoff et
al., 2004).
In diabetic patients this process is defective because of a lack of insulin and/or insulin
resistance, whereby the cells do not respond to insulin. When blood glucose levels are high,
lack of insulin function fails to suppress glucagon secretion and directly inhibit liver glucose
production. As a result, the appearance of glucose exceeds the disappearance of glucose in
the blood stream. Eventually this leads to postprandial hyperglycemia (Figure 10, right
diagram).
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(b) Low blood glucose level (fasted state)
In the fasting state, the blood glucose level decreases continually because glucose is in
constant demand by the brain, red blood cells etc. To keep pace with the glucose
disappearance, endogenous glucose production is necessary. The solesource of endogenous
glucose production is the liver. The kidneys also contribute to the blood glucose pool during
severe starvation by renal gluconeogenesis.
When the blood glucose level is lower than normal, pancreatic α-cells in the islets of
Langerhans detect the drop and secrete the hormone glucagon. Glucagon activates the
enzymes in the liver which convert glycogen into glucose and stimulates the formation of
glucose from other substances, such as amino acids, via gluconeogenesis. This glucose is
passed out into the blood raising blood glucose levels back to normal level (Figure 12).
While most tissues have the ability to hydrolyze glycogen to glucose, only the liver and
kidneys express G-6-Pase , which can release glucose into the circulation. The enzyme G-6-
Pase can hydrolyze G-6-P into a phosphate group and a free glucose. A free glucose molecule
can diffuse back to the plasma through a GLUT4 portal allowing release of glucose for use by
all the cells in the body.
In the diabetic person in the fasting state, plasma glucose is derived from
glycogenolysis and gluconeogenesis under the influence of glucagon.  Importantly,
exogenous administration of insulin can restore normal postprandial insulin concentrations in
the portal vein and to suppress glucagon through a paracrine effect (Figure 12).
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Figure 12: Glucose homeostasis at fasted state in a non-diabetic
(left) and diabetic subject (right).
(Source: Aronoff et al., 2004).
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2.3.8 Bi-hormonal model of glucose homeostasis
In the bi-hormonal model of glucose homeostasis, insulin is responsible for glucose
disappearance and glucagon is responsible for glucose appearance. After reaching a post meal
peak, blood glucose levels slowly decrease during the next several hours, eventually returning to
fasting levels. In the immediate post-feeding state, glucose removal to adipose tissue and skeletal
muscle is driven by insulin.
(a) Insulin
This is a key anabolic hormone secreted by β-cells in response to increased blood glucose levels.
The primary action of insulin is to stimulate the glucose disappearance. Insulin is a small protein
composed of two polypeptide chains containing 51 amino acids. Like many other hormones
insulin also carries out its function through binding to specific receptors present on many cells of
the body including fat, liver and muscle cells. Insulin helps to control postprandial glucose in
three ways.
1. Initially insulin signals the cells of insulin-sensitive peripheral tissues, primarily skeletal
muscle, to increase their uptake of glucose.
2. Insulin acts on the liver to promote glycogenesis.
3. Insulin simultaneously inhibits glucagon secretion from pancreatic α-cells, thus signaling
the liver to stop producing glucose via glycogenolysis and gluconeogenesis.
Altogether all of these actions reduce the blood glucose level. Other actions of insulin
include stimulation of fat synthesis, promotion of triglyceride storage in fat cells, promotion of
protein synthesis in the liver and muscle and proliferation of cell growth (Cryer, 1992).
Insulin action is carefully regulated in response to circulating glucose concentrations.
Insulin is not secreted if the blood glucose concentration is ≤ 3.3mmol/L, but is secreted in
increasing amounts as glucose concentration increases beyond this threshold (Gerich, 1993).
Postprandially the secretion of insulin occurs in two phases: an initial rapid release of
preformed insulin followed by increased insulin synthesis and release in response to blood
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glucose. Long term release of insulin occurs if glucose concentrations remain high (Cryer, 1992
and Gerich, 1993). Diabetic subjects either lack insulin or are resistant to insulin, resulting in
high blood glucose levels due to impaired glucose disposal (primarily into muscle glycogen) and
unrestrained hepatic glucose output. While glucose is the most potent stimulus of insulin, other
factors stimulate insulin secretion such as increased plasma secretion of some amino acids,
specially arginine, leucine, and lysine, GLP-1 and GIP released from the gut following a meal
and parasympathetic stimulation via the vagus nerve (Drucker, 2001 and Holst, 1994).
(b) Glucagon
Glucagon is secreted by the α-cells of the islets of Langerhans in response to low blood glucose
levels. Glucagon is a key catabolic hormone and it consists of 29 amino acids. Glucagon was
characterized as opposing the effects of insulin (Unger, 1971).  Glucagon plays a major role
sustaining plasma glucose level during the fasting state by stimulating hepatic glucose
production.
When plasma glucose levels fall, glucagon secretion increases promoting hepatic
glycogen breakdown and gluconeogenesis as well as adipose tissue lipolysis. This returns the
plasma glucose to the normal range (Gerich et al., 1979 and Orci et al., 1975). This endogenous
source of glucose is not needed during and immediately following a meal and therefore glucagon
secretion is suppressed. When coupled with insulin’s direct effect on the liver, glucagon
suppression results in a near-total suppression of hepatic glucose output (Figure 13) in the fed
state.  Glucagon is presumed to have no effect on skeletal muscle glucose metabolism as muscle
is reported not to express glucagon receptors (Tornheim and Ruderman, 2011). In the diabetic
state, there is inadequate suppression of postprandial glucagon secretion by insulin resulting in
elevated glucose production output (Figure 13) Cryer, 1981 and Dinneen et al., 1995).
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Figure 13: Insulin and glucagon secretion in diabetic and non diabetic subjects.
(Source: Aronoff et al., 2004)
2.3.9 Other hormones involved in glucose homeostasis
Although initially it was understood that circulating levels of glucose are controlled by insulin
and glucagon, later on it was revealed that other hormones play important roles in glucose
metabolism such as amylin, epinephrine, cortisol, growth hormone and the incretin hormones:
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) (Aronoff et
al., 2004). Those hormones and their glucoregulatory effects have been listed in Table 02.
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Table 02: Effects of primary glucoregulatory hormones.
Organ Hormone Function
Pancreas (α- cells) Glucagon Stimulates the breakdown of stored liver glycogen
Promotes hepatic gluconeogenesis
Promotes hepatic ketogenesis
Pancreas (β- cells) Insulin Affects glucose metabolism and storage of ingested
nutrients
Promotes glucose uptake by cells
Suppresses postprandial glucagon secretion
Promotes protein and fat synthesis
Promotes use of glucose as an energy source
Amylin Suppresses postprandial glucagon secretion
Slows gastric emptying
Reduces food intake and body weight
Intestine (L-cells) GLP-1 Enhances glucose-dependant insulin secretion
Suppresses postprandial glucagon secretion
Slows gastric emptying
Reduces food intake and body weight
Promotes β-cell health
Intestine (K-cells) GIP Induce insulin secretion
Adrenal medulla Epinephrine Enhances release of glucose from glycogen
Enhances release of fatty acids from adipose tissues
Adrenal cortex Cortisol Enhances gluconeogenesis
Antagonizes insulin
Anterior pituitary Growth
hormone
Antagonizes insulin
(Sources: Sherwinet al., 1980, Aronoff et al., 2004, Cho and Kieffer , 2010)
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(a) Amylin
Amylin is secreted by pancreatic β-cells in response to nutrient stimuli (Cooper et al., 1987,
Koda et al., 1992, Moore and Cooper, 1991, Ogawa et al., 1990). Amylin is a 37-amino acid
peptide and works along with insulin to coordinate the rate of glucose appearance and
disappearance in the circulation, thereby preventing an abnormal rise in glucose concentrations.
Studies in humans have demonstrated that the secretory and plasma concentration profiles of
insulin and amylin are similar with low fasting concentrations and increases in response to
nutrient intake (Koda et al., 1995 and Fineman et al., 1996). In subjects with diabetes, amylin is
deficient in type 1 and impaired in type 2 diabetes (Kruger et al., 1999 and Young, 1997).
(b) Incretin hormones: GLP-1 and GIP
Several incretin hormones have been identified and the dominant ones involved in glucose
homeostasis are GIP and GLP-1 (Aronoff et al., 2004). GIP stimulates insulin secretion and
regulates fat metabolism, but does not inhibit glucagon secretion or gastric emptying (Yip and
Wolfe, 2000). GIP levels are normal or slightly elevated in people with type 2 diabetes (Vilsboll
et al., 2001). While GIP is a more potent incretin hormone, GLP-1 is secreted in greater
concentrations and is more physiologically relevant in humans (Nauck et al., 1993).
GLP-1 is synthesized and secreted by the L-cells found mainly in the ileum and colon
(Aronoff et al., 2004). GLP-1 also stimulates glucose-dependent insulin secretion but is
significantly reduced postprandially in people with type 2 diabetes or impaired glucose tolerance
(Lugari et al., 2002 and Vilsboll et al., 2001). GLP-1 is secreted when gastrointestinal tract
glucose levels are high. Both GLP-1 and GIP are effectively stimulated by ingestion of a mixed
meal or meals enriched with fat and carbohydrates (Herrmann et al., 1995 and Elliott et al.,
1993).  In contrast to GIP, GLP-1 inhibits glucagon secretion and slows gastric emptying
(Matsuyama et al., 1988). GLP-1 has plasma half life of about 2 minutes (Aronoff et al., 2004).
GLP-1 has many physiological effects and they have been listed in Table 02.
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2.4 Effect of Krüppel-Like factors on glucose metabolism
It is a well known fact that disturbance of energy metabolism can result in conditions like obesity
and insulin resistance and eventually type 2 diabetes mellitus. A novel area of research is the
effect of the KLF group of transcriptional factors on body metabolism. The most well
characterized role of KLFs in metabolism is through regulation of adipocyte differentiation
(McConnell and Yang, 2010). For example in the process of adipogenesis, KLF2 is needed for
maintenance of preadipocytes but it is down regulated as differentiation proceeds (Pearsonet al.,
2008). In contrast, KLF5 and KLF 15 are positive regulators of adipogenesis.
Glucose metabolism and fat metabolism are interconnected in the human body. KLFs
also have a role in glucose metabolism and research is ongoing in order to understand the effect
of KLFs in glucose homeostasis. Table 03 presents the published findings describing the role of
KLFs in glucose metabolism in the body particularly in liver and skeletal muscle to understand
their unique functions and actions in the glucose metabolism in the body.
Table 03: Functions of KLFs on glucose metabolism.
Type of KLF Function/ Observation Reference
KLF2 Human umbilical vein endothelial cells (HUVECs)
cultured at high concentrations of glucose and observed
that KLF2 expression significantly decreased in a dose-
dependent manner.Endothelial nitric oxide synthase
(eNOS) expression was also suppressed.
According to in vivo studies using insulin resistant, type 2
diabetic rats, KLF2 was also suppressed in the vessels
showing that results were consistent with in vitro findings.
Suppression of KLF2 in diabetic rats may increase
neointimal formation and intraluminal thrombus
formation. Replenishment of KLF2 may be effective for
preventing diabetic vascular dysfunction.
Lee et al., 2012
Lee et al., 2012
KLF3 According to the experiments done in Bell-Anderson lab
it has been found that KLF3 knockout mice had increased
Unpublished
data, Bell-
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fasted plasma glucose level compared to wild type mice
whilst their insulin tolerance remained same between wild
type and klf3-/- mice.
Anderson lab.
KLF4 Evidence suggests that M2 machophages can protect
against insulin resistance and the IL-4 mediated induction
of characteristic M2 marker genes was significantly
attenuated in KLF4 deficient macrophages indicating that
KLF4 is required for optimal M2 activation.
Insulin and glucose tolerance were measured in HFD
(high fat diet)-fed myeloid specific (Mye) wild type and
knockout mice. Mye-deficient mice were more resistant to
glucose-lowering effect of exogenous insulin. In keeping
with an insulin-resistant state, phosphorylation of Akt
(protein kinase B) was reduced in liver and skeletal
muscle of Mye-deficient mice after HFD.
Liao et al., 2011
KLF5 KLF5 regulates the expression of SMemb (Embryonic
form of myosin heavy chain) in human endothelial cells.
SMemb is increased by high glucose concentration.
Glucose MEK 1 KLF5 SMemb
klf5+/–mice were resistant to high-fat diet-induced obesity
and protected from dyslipidemia, glucose intolerance and
hepatic steatosis, indicating that klf5+/– mice were less
susceptible to metabolic syndrome.
Fukuda et al.,
2007
KLF6 KLF6 was induced by high glucose in proximal tubule
kidney cells and up-regulated in the kidney of the diabetic
Ren-2 rat.
Seven binding sites of KLF6 and three binding sites of
peroxisome proliferator-activated receptor-γ (PPAR-γ)
located in the Txnip (Thioredoxin-interacting protein)
promoter region. Therefore Qi et al also hypothesized that
KLF6 and PPAR-γ may also regulate the Txnip
Holian et al.,
2008
Qi et al., 2009
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expression and promoter activity in hyperglycemic
conditions. Txnip is a critical regulator of glucose
metabolism in liver and heart and demonstrated to play a
main role in global glucose homeostasis.
KLF 7 KLF7 has been identified as a new susceptibility gene for
type 2 diabetes. It is hypothesized that KLF7 contributes
to the pathogenesis of diabetes by inhibiting insulin
synthesis and secretion from pancreatic β-cells.
The role of KLF7 in an insulin-secreting cell line (HIT-
T15) has been examined and it was shown that expression
of the insulin gene was significantly reduced in cells over-
expressing KLF7 in a dose dependent manner.
The mRNA expression of the hexokinase 2 gene in KLF7-
overexpressing L6 cells was significantly reduced
compared with that in the control cells, whereas the
change in expression of GLUT1,GLUT4, and glycogen
synthase was not statistically significant between the
control cells and KLF7-overexpressing cell.
Kanazawa et al.,
2006
McConnell and
yang, 2010
Kawamura et al.,
2006
KLF 10 Loss of KLF10 changes the expression of genes involved
in lipogenesis, gluconeogenesis and glycolysis.
KLF10 is a modulator of carbohydrate metabolism in the
liver. klf10-/- male mice exhibit hyperglycemia. The effect
has been attributed to the direct repression of the proximal
PEPCK gene promoter by KLF10.
Guillaumond et
al., 2010
KLF 11 KLF11 transgenic mice have a considerably smaller
exocrine pancreas than controls due to reduced
proliferation and increased apoptosis. Endogenous KLF11
mRNA levels were reduced by high glucose in INS-1E
beta cells.
KLF11 plays a role in glucose metabolism by regulating
the β-cell function in the pancreas and further it is
Niu et al.,2007
Neve et al., 2005
40
associated with type 2 diabetes. β-cells cultured in high
levels of glucose have higher levels of KLF11, which
activates the insulin promoter.
KLF 15 KLF15 was the first KLF to be found to be involved in
glucose metabolism i.e. gluconeogenesis.
KLF15 regulates the expression of insulin-sensitive
glucose transporter GLUT4 in both adipose tissue and
muscle tissue.
It has been shown that klf15-/- mice exhibit severe
hypoglycemia after an overnight (18 hours) fast in both
male and female mice because of decreased availability of
amino acids-derived substrates necessary for liver
gluconeogenesis.
At the same time, male and female KLF15 deficient mice
had statistically significant lower blood glucose level
compared to klf15+/+ mice in the ad libitum-fed state.
KLF15 knockout mice also had increased hepatic insulin
sensitivity.
In the fasted state, klf15-/- mice had around 3.5 fold
decreased amount of glycogen compared to wild type
mice.
Glucagon levels were increased in klf15-/- mice in both the
fed and fasted state but no difference in insulin levelswas
observed.
klf15-/- mice liver and muscle show markedly reduced
mRNA expression of amino acid degrading enzymes e.g.
alanine amino transferase.
Gray et al., 2002
Gray et al., 2007
Above table summarizes the functions of KLFs in glucose metabolism that have been discovered
so far. Krüppel-like factor 2, 3 and 10 have negative effects on glucose level whilst there is a
positive effects from KLF 4, 6, 7, 11 and 15.
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3. Methods
3.1 Animals
Mice on the background FVB/NJ strain were used in this study. Ethical approval for the use of
mice was obtained from The University of Sydney Animal Care and Ethics Committee (ACEC).
Plasma and tissue samples were obtained from male mice (n=40) as part of a cohort managed by
Mr. Hanapi Mat Jusoh (PhD candidate, Bell-Anderson lab, School of Molecular Bioscience).
Mice were housed in the School of Molecular Bioscience animal house (The University of
Sydney, NSW, Australia). They were maintained on a 12 hour dark/light cycle (lights on at 6am)
at a constant temperature of 220C ± 10C with ad libitum access to water and standard chow diet
(Glenn Forest Specialty Feeds, WA). Percentage energy from protein, fat and carbohydrate of
standard chow diet consisted of 18 %, 9 % and 73% respectively.
3.2 Identification of mice by ear-marking
At three weeks of age, mice were anaesthetized with isoflurane and given one of six unique ear
punches for identification. Tail tips (~5 mm) were taken for genotyping.
3.3 Genotyping
3.3.1 Tail digest
Tail tips were digested in 150µL Direct PCR lysis reagent with 0.13 µL proteinase K overnight
at 550C. Samples were heated to 850C for 45 minutes to inactivate proteinase K. After pulse
centrifugation in a capsule HF-120 (Tomy digital biology Co., Ltd, Tokyo, Japan) the lysate was
removed for amplification of sequences of interest by polymerase chain reaction (PCR).
3.3.2 PCR
Mice were genotyped to identify the presence of klf3 and/or Neo sequences. The primer pairs
used for the amplification reaction are shown in Table 04. For each PCR run, three positive
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controls and a non-template control (NTC) were included. The positive controls consisted of
DNA from klf3+/+, klf3-/+and klf3-/- mice. Isolated genomic DNA (2-20ng) or Baxter H2O (1µL)
was mixed with 1˟ThermoPol reaction buffer, 0.2mM dNTP and 0.8 µM of primer (Neo and klf3
fwd/rev). Finally, Taq polymerase (0.02 U/mL) was added and tubes were centrifuged for 10
seconds in a C1301-230V centrifuge (Bio-Rad Laboratories (Pacific) Pty Ltd, Gladesville, NSW,
Australia) before being loaded into a VeritiTM 96-well thermal cycler (Applied Biosystems,
Mulgrave, VIC, Australia). The PCR cycle is shown in Figure 14.
Table 04: klf3 group primer composition.
Primer Sequence
Klf3 Fwd* AAATGCACCTGGGAAGGCTGCAC
Klf3 Rev† CAGACTAGCATGTGGCGTTTCCTG
Neo Fwd* TGATGCAATGCGGCGGCTGCATAC
Neo Rev† CAGAGAACTCGTCAAGAAGGCGA
* Forward primer, †Reverse primer
Figure 14: PCR cycle.
Temperatures are shown above the line and times are shown below the line (minutes: seconds).
30 cycles
ExtensionElongationDenaturation Storage
600C
0C
200C
94 0C 72 0C 72 0C
α
5:001:002:00
0:30
94 0C
0:30
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3.3.3 Gel electrophoresis
Loading dye was added to PCR products to a final concentration of 25% (v/v) glycerol, 0.25 %
(w/v) bromophenol blue, 6mM EDTA pH 8.0. Approximately 10 µL of samples were loaded
onto a 2.0% (w/v) agarose gel made in tris acetate EDTA (TAE) buffer (40 mM Tris Acetate,
1mM EDTA, pH 8.0) and containing 0.3µg/mL ethidium bromide. The gel was run at 80V for
approximately 50 minutes in TAE and then visualized and photographed by UV
transillumination using Quantity One® software (4.1.1 Gel-Doc 2000, Bio-Rad). Gel schematic is
shown in Figure 15.
Figure 15: Schematic of klf3 genotyping.
The smaller band (170bp) represents the undisrupted klf3 gene, present in klf3+/+ and klf3+/- mice.
The larger band (450bp) represents the Neocassette inserted at the Klf3 gene locus, and present
only in klf3+/- and klf3-/-mice.
klf3 klf3 klf3
+/+              +/- -/-
-
450bp
170bp
+
Neo
Klf3
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3.4 Experimental design
In this experimental study, 20 knockouts and 20 wild type male mice were used (in some
instances, number per each group was slightly deviated depending on the available data). Each
group was divided into two in order to be in a fed or fasted state (Figure 16). We followed the
natural eating pattern of mice when selecting the time of sacrifice for the fed and fasted state.
According to the literature the eating pattern of mice follows a diurnal rhythm, mice eat the most
during the dark phase and less during the light phase. Therefore, mice were sacrificed at 9pm and
5pm considered as fed and fasted respectively.
Figure 16: Experimental design of the study.
20 wild type
Fasted
20 knock out
Fed Fed Fasted
Mice sacrifice and collection of liver, muscle and blood
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3.5 Mouse sacrifice
Body weights were recorded to the nearest 0.01g and mice were sacrificed at 13 weeks of age.
Mice were sacrificed by intraperitoneal injection of 100µL of “Lethobarb Euthansia injection”
(sodium pentobarbitone, 260mg/kg body weight). Animals were observed until they stopped
moving and death was confirmed by testing corneal reflex and absence of respiratory movement
before proceeding.
3.6 Blood collection
Blood was collected to EDTA tubes by cardiac puncture using a 26G ˟ ½” needle with a 1mL
syringe. Blood was separated by centrifugation (10 000rpm, 10 minutes at 250C temperature)
using a Hereaus Biofuge fresco centrifuge (Thermo Fisher Scientific, Waltham, MA, USA).
Plasma was transferred to fresh tubes and kept frozen at -800C until required.
3.7 Analysis of blood glucose
Immediately after blood was collected, blood glucose was measured by Accu-Chek®
Performaglucometer (Roche Diagnostics, Australia).
3.8 Tissue collection
Immediately after sacrifice of mice, liver, kidney, lung, red quadriceps muscle, white adipose
tissue (subcutaneous, retroperitoneal and gonadal) and brown adipose tissue were collected. All
were freeze clamped in liquid nitrogen and stored at -800C until required. Liver and red muscles
were used for analyzing glycogen. Liver samples were used to analyze glucose-6-phosphatasein
this study.
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3.9 Glycogen analysis of liver and red skeletal muscle
Glycogen was measured using an enzymatic assay. This assay determines glycogen by two main
reactions. First glycogen is isolated and broken down to glucose and then that glucose is
measured using a glucose oxidase based method.
A known amount of liver and muscle (approximately 20mg) were measured in to 2mL
eppendorf tubes. 1M KOH (200 µL) was added and tubes were incubated at 800C for 25 minutes
while shaking. Following this, saturated Na2SO4 (75µL) and 95% ethanol (1.725 mL) were
added. After vortexing, tubes were centrifuged at 13000rpm for 15 minutes at 40C. Subsequently,
the supernatant was discarded slowly by slanting the tubes. The pellet was resuspended in
distilled H2O (200µL) and incubated at 800C for 15 minutes while shaking until the precipitate
was completely digested. Then, 1 mL and 250 µL of prepared amyloglucosidase enzyme was
added to liver samples and muscle samples respectively (enzyme prepared fresh by mixing 3mg
of amyloglucosidase with 10mL of 0.25M, pH 4.75 acetate buffer). Finally samples were
incubated overnight at 370C while shaking.
Glycogen n glucose
1000uL or 500uL of supernatant, from muscle or liver respectively, was taken for glucose
analysis using a glucose oxidase method.
3.9.1Glucose analysis by glucose oxidase method
A series of standards were made with known concentration of glucose (0, 2, 4, 8, 12, 16 and
20mM/L) by using 5mM glucose stock solution. Of the unknown liver and muscle samples, 5 µL
and 10 µL were used respectively. Standards (0-20 mM/L) and liver/muscle samples were added
in duplicate to each well of a 96-well plate followed by300 µL of assay buffer. Assay buffer was
a mixture of phosphate buffer (25 µL), dye (50 µL), peroxidase (25 µL) and glucose oxidase
(125µL). The covered plate was incubated at 370C for about 20 minutes to allow sufficient time
for the reaction to complete. Readings were taken at 492nm by a plate reader (Thermoscientific,
Waltham, MA, USA).
Amyloglucosidase
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3.9.2 Optimization of glycogen assay
To determine the optimal reaction conditions in order to have confidence in our results, different
volumes of the same liver homogenate were used while maintaining all other conditions
constant.
Figure 17 shows liver glycogen content determined in different volumes of liver extract
from the same liver sample. With the increase of volume of extract, liver glycogen content
increased. There was a strong correlation between the volume of liver extract and liver glycogen
content. Therefore, the minimum volume of 5µL was chosen as the volume of extract to be
assayed. As a first step, liver glycogen content of KLF3 knockout and wild type mice in the fed
and fasted state were determined. As mentioned in the methodology, an enzymatic assay was
used to measure liver and muscle glycogen levels.  This methodology was optimized using spare
liver samples before the assay was performed on liver and muscle from klf3-/- and klf3+/+
animals.
Figure 17: Correlation graph between volume of liver samples and liver glycogen contents.
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3.10 Glucose-6-phosphatase activity
Glucose-6-phosphatase activity was determined using a radioactive isotope method in which a
known amount of radioactive glucose-6-phosphate ([U-14C]G-6-P) was used to react with the
glucose-6-phosphatase enzyme present in liver to form glucose.
Approximately 50mg of liver tissue was homogenized using a Polytron (Kinematica INC,
Luceerne, Switzerland) at 13,000rpm speed in 20 volumes of homogenizing buffer.
Homogenizing buffer was composed of Triethanolamine HCl (TRA) (100mM), magnesium
chloride (5mM), EDTA (5mM), potassium chloride (100mM), DTT (2mM) dissolved in distilled
water. Assay buffer (50µL) and homogenate (50µL) were incubated together at 300C. The assay
buffer contained MoPS (50mM), [U-14C] G-6-PO4 and cold glucose-6-phosphate (5mM). After
10 minutes, the reaction was terminated by adding FeCl3 (60mM, pH=6) and centrifuged for 5
minutes at 12000rpm to precipitate proteins and G-6-PO4. Finally, the supernatant was taken for
radioactivity counting and G-6-PO4ase activity was measured as µmol of glucose from G-6-P per
gram of liver tissue.
3.10.1 Optimization of Glucose-6-phosphatase activity assay
As mentioned in the methodology, glucose-6-phosphatase activity was measured using a
radioactive labeled isotope protocol. Before applying the methodology to measure glucose-6-
phosphatase enzyme activity in actual liver samples, the conditions were optimized using a test
liver sample. The aim of optimization was to determine the optimal reaction time in order to
obtain consistent and reliable results. The graph below shows the results of initial glucose-6-
phosphatase activity measurements.
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Figure 18: Glucose-6-phoshatse activity versus reaction time.
3.11 Plasma glucagon analysis
Plasma glucagon concentration was determined using Alpco® rat, mouse and human glucagon
EIA (Enzyme Immunoassay) (Alpco Diagnostics Inc, Salem, NH, USA). The EIA kit for
determination of rat, mouse or human pancreatic glucagon in plasma samples is based on a
competitive enzyme immunoassay using a combination of a highly specific antibody to glucagon
and a biotin-avidin affinity system (Figure 19).
Figure 19: Schematic of EIA.
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1. Antigen-specific polyclonal antibody is attached to a solid-phase surface, 2. Plasma is added,
which contains antigen (glucagon) in the plasma and this will bind to the antibody, 3.An
enzyme-labeled antibody specific to the antigen is added (conjugate), 4.Chromogenic substrate is
added, which in the presence of the enzyme, changes color.
First, undiluted plasma, standards (0-10000pg/mL) were added in duplicate to each well of a 96-
well plate. The 96-well plate was precoated with a rabbit anti-glucagon antibody. Next, labeled
antigen (50µL) was added to the wells for competitive immunoreaction. The plate was incubated
at 4°C for 48 hours to allow glucagon to bind to the polyclonal antibodies on the plate surface.
The plate was washed three times with a wash solution provided (approximately 0.35 mL/well)
and tapped to dry and remove unbound antigen.
After incubation and plate washing, HRP labeled streptoavidin (SA-HRP) was added
followed by one hour incubation while shaking at room temperature to form HRP labeled
streptoavidin-biotinylated pancreatic glucagon-antibody complex on the surface of the wells.
Then wells were again washed three times with the wash solution provided. Finally, a substrate
solution containing O-phenylenediamine dihydrochloride (OPD) (100µL) was added to the wells
and incubated for 20 minutes at room temperature and the reaction terminated by addition of a
stop solution. The optical absorbance of the wells was read at 490 nm immediately after stopping
the color reaction. Finally, HRP enzyme activity was determined by OPD and the concentration
of mouse pancreatic glucagon was calculated. Standard curve used for the glucagon analysis is
shown in the Figure 20.
Figure 20: Glucagon standard curve.
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3.12 Statistical analysis
The mean and standard deviation values were calculated for all data obtained. Values lower and
higher than two standard deviations above or below the mean were excluded from the analysis
which is considered as a quantitative method of exclusion of outliers. StatView version 4.57
(Abacus concepts Inc, Berkeley, CA, USA) was used for statistical analysis. Unpaired, two tailed
t tests were used to determine significant differences between groups. A P value < 0.05 was
considered statistically significant.
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4. Results
4.1 KLF3 knockout mice have significantly lower body weight than wild type mice at the
time of sacrifice.
Figure 21: Comparison of body weight of KLF3 knockout mice and wild type mice. Values are
the mean ± s.e.m of 24-27 animals. *P < 0.05 as compared with wild type mice.
We observed that KLF3 knockout mice had significantly lower body weight at the time of
sacrifice (p value = 0.003). Wild type mice had mean body weight of 32.0 ± 1.9 g whereas KLF3
knockout mice had 28.1 ± 2.5g. We also observed that KLF3 knockout mice are smaller in size
compared to their wild type liter mates.
4.2 Food intake data of wild type and KLF3 knockout mice in the fed and fasted state.
Figure 22 shows food intake within 12 hours of wild type and KLF3 deficient mice for fed and
fasted state. Food intake of wild type mice was significantly lower during natural fasting state
than that of night time (fed state) food intake.  There was no difference in food intake data
between the fed and fasted state of KLF3 knockout mice.
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Figure 22: Comparison of food intake of KLF3 knockout mice and wild type mice at fed and
fasted state. Values are the mean ± s.e.m of 9-10 animals. *P < 0.05 as compared with fed state.
4.3 KLF3 knockout mice have higher fasting blood glucose level in the fasted state.
We compared the blood glucose levels of KLF3 knockout mice and wild type mice in this study.
Mice maintained their normal eating pattern in which we considered 4-5pm as a fasted state and
9pm as a fed state. KLF3 deficient mice had significantly higher blood glucose levels in the
fasted state compared with wild type mice (Figure 23). Further experiments were designed to
investigate mechanisms underlying the higher blood glucose levels in KLF3 mice. We initially
hypothesized that the higher fasting blood glucose levels in KLF3 knockout mice could be due to
increased glycogen breakdown or increased gluconeogenesis in the fasted state.
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Figure 23: Comparison of blood glucose levels in KLF3 knockout and wild type mice in the fed
and fasted state. Values are the mean ± s.e.m of 9-11 animals. *P < 0.05 as compared with wild
type mice.
4.4 Insulin levels are unchanged in KLF3 knockout mice in the fed state.
Figure 24 shows the plasma insulin levels of KLF3 knockout and wild type mice in fed and
fasted state. No differences were seen in insulin levels in fed state however KLF3 knockout mice
had significantly higher insulin level in fated state.
Figure 24: Comparison of plasma insulin levels in KLF3-/- and KLF3+/+ mice in the fed state.
Values are the mean ± s.e.m of 10-13 animals. *P < 0.05 as compared with wild type mice.
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4.5 Klf3-/- mice have lower liver glycogen levels in the fed state.
Liver glycogen content in wild type and KLF3 knockout mice in the fed and fasted state were
measured and the results are shown in Figure 25. Liver glycogen in the fed state in KLF3
knockout mice was lower than that of wild type mice suggesting that wild type mice may have
higher liver glycogen storing capacity. There was no significant difference in glycogen content
of KLF3 knockout mice and wild type mice in the fasted state.
Figure 25: Comparison of liver glycogen in klf3-/-and klf3+/+mice in the fed and fasted state.
Values are the mean ± s.e.m of 12-15 animals. *P < 0.05 as compared with wild type mice.
4.6 Muscle glycogen levels in KLF3 knock out and wild type mice in fed and fasted state are
unchanged.
Figure 26 shows the muscle glycogen content of KLF3 knockout mice and wild type mice. We
found no significant difference in the glycogen content of skeletal muscle of knock out and wild
type mice either in the fed or fasted state.
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Figure 26: Comparison of muscle glycogen in klf3-/- and wild type mice in fed and fasted state.
Values are the mean ± s.e.m of 9-10 animals.
4.7 KLF3 knockout mice have higher liver glucose-6-phophatase activity compared to wild
type mice in the fed state.
The following graph shows the liver glucose-6-phosphatase activity in wild type and KLF3
knockout mice in the fed and fasted state.
Figure 27: Comparison of liver G-6-Pase activity in klf3-/- and klf3+/+mice in the fed and fasted
state. Values are the mean ± s.e.m of 9-11 animals.*P < 0.05 as compared with wild type mice.
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Figure 27 illustrates that there is a significant difference in the glucose-6-phosphatase activity
between wild type and KLF3 knockout mice in the fed state but not in the fasting state. In the fed
state, KLF3 knockout mice had significantly higher glucose-6-phosphatase activity compared to
their wild type litter mates.
4.8 Plasma glucagon levels of KLF3 knockout and wild type mice in the fasted state are not
different.
Glucagon is a pancreatic hormone that acts to increase blood glucose levels when the blood
glucose level falls. Plasma glucagon levels were measured by using an Enzyme Immunoassay
(EIA) kit as mentioned in the methodology.
As shown in Figure 28, there was no significant difference in the plasma glucagon
content of wild type and KLF3 knockout mice.
Figure 28: Plasma glucagon content of wild type and KLF3 knockout mice in the fasted state.
Values are the mean ± s.e.m of 9-11 animals.
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5. Discussion
We compared the blood glucose levels of KLF3 knockout mice and wild type mice in this study
and observed that KLF3 deficient mice had significantly higher blood glucose levels in the fasted
state. In the fed and fasted states in these experiments, mice were not food restricted and
continued their normal diurnal food consumption pattern. Usually mice eat more during the night
time and less during the day time. Therefore, mice sacrificed between 9pm and 10pm were
considered as in the fed state whilst 4-5pm in a naturally fasted state. Our food intake data
showed that there is a significant difference of food intake of wild type mice during the day time
and night time. Wild type mice eat a significantly greater amount of food during the night time
(fed state) than day time (fasted state). There is no significance difference of food intake of
KLF3 knockout mice in fed and fasted state and they eat more food in fasted state than that of
wild type mice.
According to our results, plasma insulin levels in KLF3 deficient mice are not significantly
different from wild type mice in the fed state but both groups had higher insulin level than their
fasted state. KLF3 lacking mice had higher plasma insulin level in the fasted state. Insulin
hormone action is arguably more important during the fed state as it is responsible for lowering
blood glucose levels to normal after a meal. The reason for having significantly higher plasma
insulin level in KLF3 knockout mice in fasted state could be because they eat more food in the
afternoon which we considered as a fasted state in natural feeding. Higher food intake can
increase the plasma insulin level in order to reduce the glucose level. Therefore higher food
intake of KLF3 knockout mice in afternoon (fasted state), can lead to higher insulin level
responding to their higher blood glucose level. By this way, our insulin results of KLF3
knockout mice comply the observation of higher fasting plasma glucose level of them. We also
investigated other mechanisms that could potentially result in increased fasting glucose levels.
Therefore we hypothesized that the higher fasting blood glucose levels in KLF3 knockout mice
could be due to increased glycogen breakdown, increased gluconeogenesis or increased glucagon
levels in the fasted state.
Results from this study demonstrated that KLF3 knockout mice are smaller in body weight
than that of wild type mice. Moreover, according to previous findings of our lab, KLF3 deficient
mice have smaller organs as a percentage of body weight compared to wild type mice.
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According to our results, liver glycogen in the fed state in KLF3 knockout mice was lower
than that of wild type mice suggesting that wild type mice may have higher liver glycogen
storing capacity. There was no significant difference in glycogen content of KLF3 knockout
mice and wild type mice in the fasted state but KLF3 knockout mice eat more during afternoon
where we considered as the fasted state. Even though knockout mice have smaller body weight,
still the results remain unchanged as the values shown here are corrected for liver weight. The
lower glycogen content of KLF3 knockout mice reflects that they may have reduced storage
capacity of glycogen in the liver also. Other reasons that may explain these results are that KLF3
knockout mice break down liver glycogen at a faster rate than wild type mice or wild type mice
eat more and store more than knockout mice during the fed state and have higher activity of
glycogen synthetic enzymes like glycogen synthase or lower activity of glycogen breakdown
enzymes such as glycogen phosphorylase or lower glucagon levels responsible for glycogen
breakdown.
In studies by Chen et al. (1992) , mice followed a diurnal eating pattern and both lean and
gold thioglucose induced (GTG) obese mice had more liver glycogen during the night time
lowering towards morning and day time irrespective of the fact that they were lean or obese. Our
‘fed’ glycogen stores may not be at same capacity, although the levels seem consistent with the
findings of the Chen et al. (1992) study. Our results may differ because of a slight change and
time shift for our results (lights of Animal house of School of Molecular Bioscience are off at
6pm, theirs are at 8pm).
There may be a different picture of liver glycogen levels at complete 16hour fasted state in
wild type and knockout mice. In a completely fasted state (16hr in which no food is available),
liver glycogen stores would be depleting at faster rate and we could observe how fast wild type
and knockout mice use liver glycogen.  In a completely fasted state and the point where food
consumption is lower, the body is physiologically in two different conditions which can affect
the switch between different metabolic pathways.
Diurnal glycogen depletion and glucose release of the body can be affected by signals from
the central nervous system.  La Fleur (2003) has reported that the daily rhythm of plasma glucose
concentration depends on the biological clock, which is located in the hypothalamic
suprachiasmatic nucleus (SCN). Therefore the daily fluctuation in plasma glucose concentration
describes a clear 24-hr rhythm (La Fleur, 2003). These fluctuations depend on food intake,
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hepatic glucose production and /or changes in glucose tolerance. Mice, like other rodents, are
active at night and their plasma glucose and insulin levels are higher during the night
corresponding to greater food intake (La Fleur, 2003).
Unlike in the liver, we found no significant difference in red skeletal muscle glycogen
content in KLF3 knock out and wild type mice either in the fed or fasted state. According to
Chen et al. (1992) experiments performed in GTG obese and lean mice, there was no significant
difference in muscle glycogen content at any point of study despite the constant
hyperinsulinemia or hyperglycemia. This observation could be because this is the maximal
capacity of which muscle can store glycogen or that muscle glycogen metabolism is independent
of insulin and glucose concentration (insulin resistance) (Chen et al., 1992).  However, in both
groups muscle glycogen content demonstrated a strong diurnal rhythm that related to the pattern
of food consumption in lean animals and the glycogen content in muscle from lean and GTG
obese mice decreased significantly during the post absorptive phase (12:00h – 18:00h) (Chen et
al., 1992).
As previously mentioned, in these experiments, fasted state was considered at the time point
when mice consume least food compared to rest of the day. So that was not the complete fasted
state in which mice depleted most of blood glucose, liver glycogen and switch to the peripheral
muscle glycogen metabolism as a source of glucose for muscle. Therefore it is not a surprise that
both knockout and wild type mice have more or less similar glycogen levels at the fed and fasted
state.
Next we aimed to measure liver glucose-6-phosphatase activity, because this is the enzyme
which breaks down glucose-6-phosphate to glucose in gluconeogenesis and glycogenolysis
processes resulting in an increased release of glucose into the circulation. This enzyme is present
in the liver and kidneys. As mentioned in the methodology, glucose-6-phosphatase activity was
measured using a radioactive labeled isotope protocol. Before applying the methodology to
measure glucose-6-phosphatase enzyme activity in actual liver samples, the conditions were
optimized using different volumes of a test liver sample. The aim of optimization was to
determine the optimal reaction time in order to obtain consistent and reliable results. As shown in
Figure 18 (3.10.1 section), as the reaction time increased, glucose-6-phosphatase enzyme activity
markedly increased and became more or less constant after 10 minutes. At the minus 5 minute
time point, the reaction terminating solution (FeCl3) was added to samples 5 minutes before the
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assay buffer. Therefore the reaction was unable to proceed. Moreover, the zero time point
indicates the point at which FeCl3, and assay buffer were added to sample at the same time again
not having time for the reaction to begin. Our assay results indicate that maximum activity of the
enzyme is measurable after 10min, therefore, in the experiments we allowed the assay to proceed
for 10 minutes in order to obtain accurate and consistent glucose-6-phosphatase activity
measurements.
There was a significant difference in the glucose-6-phosphatase activity between wild type
and KLF3 knockout mice in the fed state but not in the fasting state. In the fed state, KLF3
knockout mice had significantly higher glucose-6-phosphatase activity. This result complements
our liver glycogen content findings (4.5 section) because in the fed state, liver glycogen content
of wild type mice was significantly higher than that of KLF3 deficient mice.  Glucose-6-
phosphatase is an enzyme which breaks down glucose-6-phosphate into glucose when glucose is
needed in the fasted state. Our results suggest that KLF3 knockout mice have lost the ability to
lower glucose-6-phoshatase enzyme activity appropriately in the fed state, and this may be a
contributing factor to the lower glycogen levels.
Gaedner et al. (1993) demonstrated that inhibition of glucose-6-phosphatase results from the
action of insulin to control hepatic glucose production. According to our measurement of plasma
insulin, we found no significant difference in plasma levels between KLF3 deficient and wild
type mice in the fed state. In the fed state insulin is the responsible hormone, which stimulates
postprandial blood glucose levels to return to normal. In the fed state, there is no or little
activation of glucose-6-phosphatase under normal conditions, because glucose-6-phosphatase in
an enzyme which facilitates glycogen breakdown. This is also reflected by our results. At fasted
state, wild type mice have higher enzyme activity while at fed state they have lower enzyme
activity which is as expected although not significantly different.
Not only glucose-6-phosphatase but other rate limiting enzyme such as PEPCK and pyruvate
dehydrogenase are involved in the different glucose metabolic pathways such as gluconeogenesis
and glycogenolysis. Guillaumond et al. (2010) reported that KLF10 knock out male mice exhibit
hyperglycemia and the effect has been attributed to the direct repression of the proximal PEPCK
gene promoter by KLF10.
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There was no significant difference in the plasma glucagon content of wild type and KLF3
knockout mice in 16 hour fasted state. This finding confirms that the fasting blood glucose level
of KLF3 knockout mice was not due to changed glucagon level.
When analyzing all above parameters in KLF3 knock out and wild type mice, it seems that
the higher fasting blood glucose level along with increased plasma insulin level is not due to
increased glycogen content, increased glucose-6-phosphatase activity or glucagon levels in the
KLF3 knockout mice. Therefore there can be other mechanisms resulting in increased glucose
level in the blood stream during the fasted state of KLF3 knockout mice. A potential mechanism
could be gluconeogenesis which releases glucose into blood stream from non carbohydrate
sources during fasted state. This could be tested by measuring gluconeogenesis precursors such
as pyruvate, glycerol, lactate or rate limiting enzymes of gluconeogenesis such as pyruvate
carboxylase, PEPCK and phosphoglycerate kinase. In overall, there is an effect of KLF3 on
glucose metabolism in the fed state but in order to get a clear picture, further analysis should be
done.
One of the main constraints of our study was the substantial time period needed to generate
the required number of KLF3 knockout mice due to the fact that only ~17percent of offspring are
knockouts due to low survival rate because of developmental problems in the womb. If our
sample size is too small, it would be difficult to find significant relationships from the data, as
statistical tests normally require a considerable sample size to ensure a representative distribution
of the population however, we were able to get minimum number of KLF3 knockout mice for
the study after considerable time.
Lack of available and/or reliable data on the studies of Krüppel like factor 3 was another
limitation for the study. Investigation of KLF3 function is a relatively new area or research and
availability of literature is fairly limited.  Sometimes, a lack of data or of reliable data would
likely require us to limit the scope of our analysis or it could be a significant obstacle in finding a
trend and a meaningful relationship. Furthermore, lack of prior research studies on the
topic limits citing prior research studies and reduces the foundation for understanding the
research problem under investigation. Due to time and financial constraints, I regret not
including data on some other parameters listed under the future directions of research section,
which are required for a better understanding to address the research question. There is need in
future research to revise some methods for gathering data such as complete fasting over natural
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fasting or both in order to show that there are any differences between those conditions on
parameters measured. We also had to rely on some available pre-existing data which can be a
constraint for the study. Longitudinal effect is another problem of our study. The time available
to investigate a research problem and to measure change or stability within a sample is
constrained by limited time.
Aim of the study was to find the underlying mechanism for increased fasting blood glucose
level observed in KLF3 knockout mice. Results of the study showed that increased fasting
glucose level is not resulted from increased hepatic glycogen content, increased glucose-6-
phosgatase or increased glucagon hormone level. However, increased fasting blood glucose level
can be resulted from increased gluconeogenesis. Therefore other possible parameters that can be
analyzed in future research can include analyzing of different enzymes (PEPCK) (activity/
concentration) and substrates (glycerol, pyruvate, and lactate) present during gluconeogenesis.
Moreover, another area could be looking at them RNA expression levels of key enzymes
involved in fatty acid oxidation [CPT 1 (carnitine palmitoyltransferase) and MCAD (medium-
chain acyl-CoA dehydrogenase)] and gluconeogenesis [phosphoenolpyruvate carboxykinase
(PEPCK) which converts oxaloacetate into phosphoenolpyruvate and carbon dioxide].
Glucose metabolism is a very complex inter-related metabolic process in the body and it can
be affected by so many other factors at different levels such as GLUT4, antioxidant status,
inflammatory factors (M1 and M2 macrophage phenotypes).  KLF is a group of transcriptional
factors and there could be inhibitory and activation effects of other KLFs on KLF3 which might
be interesting in relation to glucose metabolism. Therefore other future research could be based
on examining synergetic and antagonist effects of other transcriptional factors in KLF group on
KLF3 in regulation of glucose metabolism.
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6. Conclusions
These results suggest that KLF3 may play a role in glucose metabolism and contributes to the
regulation of glycogen synthesis and/or degradation in the liver in the fed state.
However there is no difference in glycogen content of KLF3 knockout and wild type
mice in the fasted state suggesting that increased fasting blood glucose levels in KLF3 deficient
mice is not associated with changes in glycogen content of the liver. Since KLF3 knockout mice
have significantly lower glycogen content in their livers in the fed state than that of wild type
mice, we conclude that KLF3 knockout mice have poor glycogen storage capacity and KLF3
may alter liver glycogen storage in the fed state. In addition, KLF3 does not appear to have any
effect on skeletal muscle glycogen storage in the fed and fasted state.
Furthermore, KLF3 knockout mice have significantly higher glucose-6-phosphatase
enzyme activity in the fed state than that of wild type mice implying that KLF3 may regulate the
glucose-6-phosphatase activity in the fed state. Klf3-/- mice have more or less same glucose-6-
phosphatase enzyme activity in the fed and fasted status indicating that glucose-6-phosphatase
system is not suppressed in the fasted state in KLF3 knockout mice.
Plasma glucagon hormone responsible for glucose homeostasis was not affected by KLF3
deficiency. However, increased insulin level in KLF3 knockout mice in fasted state partly
explained by the higher food intake. Therefore overall, increased fasting blood glucose level of
KLF3 knockout mice does not appear to be associated with increased liver glycogen content,
increased glucose-6-phosphatase enzyme activity and/or increased glucagon level.
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